At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 164 enrolled
Drug / intervention
ETS6103 (low dose) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double Blind, Non-inferiority Study to Evaluate the Antidepressant Activity of ETS6103 Compared to Amitriptyline in Treating Major Depressive Disorder in Patients With Unsatisfactory Response to Selective Serotonin Re-uptake Inhibitors.
In Brief
A Phase 2 clinical trial evaluating ETS6103 (low dose), ETS6103 (high dose), and 1 other intervention for Major Depressive Disorder. Completed, enrolled 164 participants across 1 site.
Detailed Summary
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedDec 2013
Primary CompletionOct 2015
TodayJul 2026
First PostedDec 18, 2013
Enrollment StartOct 1, 2013
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.5 years ago
Interventions
ETS6103 (low dose)drug
ETS6103 (high dose)drug
Amitriptylinedrug